• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cardiol Therapeutics Inc. (Amendment)

    2/7/22 4:38:31 PM ET
    $CRDL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRDL alert in real time by email
    SC 13G/A 1 formsc13ga.htm FORM SC 13G/A MMCAP International Inc. SPC: Form SC 13G/A - Filed by newsfilecorp.com

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G/A

    AMENDMENT NO. 1

    INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    Cardiol Therapeutics Inc.

    (Name of Issuer)


    Common Shares

    (Title of Class of Securities)


    14161Y200

    (CUSIP Number)


    December 31, 2021

    (Date of Event Which Requires Filing of This Statement)

    Check the Appropriate box to designate the rule pursuant to which this schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)


    CUSIP No. 14161Y200

    13G/A

    Page 2 of 6 Pages


    1

    NAME OF REPORTING PERSONS
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

     

    MMCAP International Inc. SPC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☑
    (b) ☐

     


    3

    SEC USE ONLY

     


    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,800,000*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,800,000*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,800,000*

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ☐

     


    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.55%**

    12

    TYPE OF REPORTING PERSON*

     

    CO

    FOOTNOTES

    * Consists of 3,153,200 common shares and warrants to purchase an additional 1,646,800 common shares.
    ** The percentages used herein are calculated based on 61,925,499 outstanding shares of the Issuer, plus 1,646,800 common shares in underlying warrants which are beneficially owned by the reporting person and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.


    CUSIP No. 14161Y200

    13G/A

    Page 3 of 6 Pages


    1

    NAME OF REPORTING PERSONS
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

     

    MM Asset Management Inc.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☒
    (b) ☐

     


    3

    SEC USE ONLY

     


    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Ontario, Canada

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    4,800,000*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    4,800,000*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,800,000*

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ☐

     


    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.55%**

    12

    TYPE OF REPORTING PERSON*

     

    CO

    FOOTNOTES

    * Consists of 3,153,200 common shares and warrants to purchase an additional 1,646,800 common shares.
    ** The percentages used herein are calculated based on 61,925,499 outstanding shares of the Issuer, plus 1,646,800 common shares in underlying warrants which are beneficially owned by the reporting person and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.


    CUSIP No. 14161Y200

    13G/A

    Page 4 of 6 Pages

    Item 1 (a). Name of Issuer:

    Cardiol Therapeutics Inc.

    Item 1 (b). Address of Issuer's Principal Executive Offices:

    602-2265 Upper Middle Road East, Oakville, Ontario, Canada, L6H 0G5

    Item 2 (a). Name of Person Filing:

    i) MMCAP International Inc. SPC

    ii) MM Asset Management Inc.

    Item 2 (b). Address of Principal Business Office or, if None, Residence:

    i) c/o Mourant Governance Services (Cayman) Limited

    94 Solaris Avenue

    Camana Bay, P.O. Box 1348
    Grand Cayman, KY1-1108, Cayman Islands

    ii) 161 Bay Street
    TD Canada Trust Tower Ste 2240
    Toronto, ON M5J 2S1 Canada

    Item 2 (c). Citizenship:

    i) Cayman Islands
    ii) Ontario, Canada

    Item 2 (d). Title of Class of Securities:

    Common Shares

    Item 2 (e). CUSIP Number:

    14161Y200

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     (a) ☐ Broker or dealer registered under Section 15 of the Act;

     (b) ☐ Bank as defined in Section 3(a)(6) of the Act;

     (c) ☐ Insurance Company as defined in Section 3(a)(19) of the Act;

     (d) ☐ Investment Company registered under Section 8 of the Investment Company Act;

     (e) ☐ Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     (f) ☐ Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F);

     (g) ☐ Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G);

     (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;


    CUSIP No. 14161Y200

    13G/A

    Page 5 of 6 Pages

     (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940:

     (j) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(j).

     ☒ If this statement is filed pursuant to Rule 13d-1(c), check this box.

    Item 4. Ownership.

     Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1.

     (a) Amount beneficially owned: 4,800,000*

     (b) Percent of class:  7.55%**

     (c) Number of shares as to which such person has:

     (i) Sole power to vote or to direct the vote:  0

     (ii) Shared power to vote or to direct the vote:  4,800,000*

     (iii) Sole power to dispose or to direct the disposition of:  0

     (iv) Shared power to dispose or to direct the disposition of: 4,800,000*

    * Consists of 3,153,200 common shares and warrants to purchase an additional 1,646,800 common shares.

    ** The percentages used herein are calculated based on 61,925,499 outstanding shares of the Issuer, plus 1,646,800 common shares in underlying warrants which are beneficially owned by the reporting person and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.

    Instruction.  For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1).

    Item 5. Ownership of Five Percent or Less of a Class.

     If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     N/A

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     N/A

    Item 8. Identification and Classification of Members of the Group.

     N/A

    Item 9. Notice of Dissolution of Group.


    CUSIP No. 14161Y200

    13G/A

    Page 6 of 6 Pages

     N/A

    Item 10. Certification.  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    MMCAP International Inc. SPC

     

     

    Date: February 7, 2022

    By: /s/ Matthew McIsaac

    ____________________________

     

          Name: Matthew McIsaac

          Title: Director

     

     

     

     

     

     

     

    MM Asset Management Inc.

     

     

    Date: February 7, 2022

    By: /s/ Hillel Meltz

    ____________________________

     

          Name: Hillel Meltz

          Title: President



    Get the next $CRDL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRDL

    DatePrice TargetRatingAnalyst
    6/2/2025$9.00Buy
    H.C. Wainwright
    1/28/2025$7.00Buy
    Rodman & Renshaw
    6/26/2024$10.00Buy
    ROTH MKM
    4/22/2024$9.00Buy
    H.C. Wainwright
    12/17/2021$8.00Overweight
    Cantor Fitzgerald
    12/3/2021$8.00Buy
    Canaccord Genuity
    More analyst ratings

    $CRDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Cardiol Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $9.00

      6/2/25 8:50:52 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on Cardiol Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $7.00

      1/28/25 7:11:43 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ROTH MKM initiated coverage on Cardiol Therapeutics with a new price target

      ROTH MKM initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $10.00

      6/26/24 8:07:20 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDL
    SEC Filings

    See more
    • SEC Form 6-K filed by Cardiol Therapeutics Inc.

      6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)

      5/29/25 7:30:12 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Cardiol Therapeutics Inc.

      6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)

      5/27/25 7:29:20 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Cardiol Therapeutics Inc.

      6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)

      5/14/25 4:37:01 PM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

      Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated April 10, 2025.Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: Jennifer Chao, David E

      5/29/25 7:27:00 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

      Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on May 28, 2025, at 4:30 p.m. EDT.Cardiol Therapeutics' 2025 AGMWhen: May 28, 2025, at 4:30 p.m. EDTWhere: Virtual meeting only via live audio webcast online at: web.lumiagm.com/226536161Additional information about the AGM, including details on how to participate and vote, is available on the Company's website at card

      5/27/25 7:27:00 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

      Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experienceToronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D., has been nominated to stand for election to the Company's Board of Directors at its 2025 Annual General Meeting of shareholders to be held on May 28, 2025.Dr. Garnett is a distinguished pharmaceutical industry executive with over 30 y

      4/29/25 7:27:00 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDL
    Leadership Updates

    Live Leadership Updates

    See more
    • Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

      Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated April 10, 2025.Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: Jennifer Chao, David E

      5/29/25 7:27:00 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

      Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "Meeting") held virtually via live audio webcast, on June 26, 2024. Shareholders voted in favour of all management resolutions proposed in the Company's management information circular dated May 13, 2024.Resolutions proposed and approved at the Meeting were:The election of the following directors for the

      6/27/24 12:29:00 PM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiol Therapeutics Reports Results of 2023 Annual General Meeting

      Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2023. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular. Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: David Elsley, Peter Pekos, Dr. Gui

      6/29/23 10:19:00 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cardiol Therapeutics Inc.

      SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)

      11/6/24 2:59:55 PM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cardiol Therapeutics Inc. (Amendment)

      SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)

      2/13/24 1:01:41 PM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cardiol Therapeutics Inc. (Amendment)

      SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)

      2/14/23 11:52:10 AM ET
      $CRDL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care